Article information
Full text is only aviable in PDF
Bibliografía
[1.]
Grupo de trabajo sobre GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Madrid: Plan Nacional para el SNS del MSC. Instituto Aragonés de Ciencias de la Salud-I+CS; 2007. Guías de Práctica Clínica en el SNS: I+CS N,° 2006/0I. 2007.
[2.]
G. Guyatt, A.D. Oxman, E.A. Akl, R. Kunz, G. Vist, J. Brozek, et al.
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.
J Clin Epidemiol, 64 (2011), pp. 383-394
[3.]
Grupo de trabajo de la guía de práctica clínica sobre Atención Integral al paciente con Enfermedad Pulmonar Obstructiva Crónica (EPOC).
Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y Sociedad Española de Medicina de Familia (semFYC), (2010),
[4.]
C.M. Marzo, P. Alonso-Coello, Clasificación de la calidad de la evidencia y fuerzade las recomendaciones. GRADE Working Group.
Aten Primaria, (2006), pp. 37
[5.]
D. Postma, A. Anzueto, P. Calverley, C. Jenkins, B.J. Make, F.C. Sciurba, et al.
A new perspective on optimal care for patients with COPD. A new perspective on optimal care for patients with COPD.
Prim Care Respir J, 20 (2011), pp. 205-209
[6.]
D.K. McKenzie, M. Abramson, A.J. Crockett, N. Glasgow, S. Jenkins, C. McDonald, on behalf of The Australian Lung Foundation, et al.
The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease, (2010),
[7.]
National Institute for Health and Clinical Excellence (NICE).
Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre; 2010, (2010),
[8.]
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Revised 2011). [sede Web]. GOLD 2011 [acceso 10 Ene 2012]. Disponible en: http://www.goldcopd.org/. 2011.
[9.]
A. Qaseem, T.J. Wilt, S.E. Weinberger, N.A. Hanania, G. Criner, M.T. Van der, et al.
Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians. American Thoracic Society, and European Respiratory Society.
Ann Intern Med, 155 (2011), pp. 179-191
[10.]
R.G. Barr, J. Bourbeau, C.A. Camargo, F.S.F. Ram.
Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis.
Thorax, 61 (2006), pp. 854-862
[11.]
Agencia Española de Medicamentos y Productos Sanitarios [sede Web]. (acceso 2 Nov 2011). Disponible en: https://sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=detalleForm.
[12.]
G.J. Rodrigo, L.J. Nannini.
Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis.
Pulm Pharmacol Ther, 20 (2007), pp. 495-502
[13.]
C. Vogelmeier, B. Hederer, T. Glaab, H. Schmidt, M.P. Rutten-van Molken, K.M. Beeh, et al.
Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
N Engl J Med, 364 (2011), pp. 1093-1103
[14.]
V.K. Shukla, S. Chen, M. Boucher, S. Mensinkai, R. Dales.
Long-acting β2-agonists for the maintenance treatment of chronic obstructive pulmonary disease in patients with reversible and nonreversible airflow obstruction: a systematic review of clinical effectiveness.
Canadian Coordinating Office for Health Technology Assessment, (2006),
[15.]
M. Neyt, A. Van den Bruel, J. Gailly, N. Thiry, S. Devriese.
Tiotropium in the treatment of chronic obstructive pulmonary disease: Health Technology Assessment.
Health Technology Assessment (HTA), Belgian Health Care Knowledge Centre (KCE), (2009),
[16.]
O. Kornmann, R. Dahl, S. Centanni, A. Dogra, R. Owen, C. Lassen, et al.
Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
Eur Respir J, 37 (2011), pp. 273-279
[17.]
S. Korn, E. Kerwin, S. Atis, C. Amos, R. Owen, C. Lassen.
Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study.
Respir Med, 105 (2011), pp. 719-726
[18.]
R. Dahl, K.F. Chung, R. Buhl, H. Magnussen, V. Nonikov, D. Jack, et al.
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
Thorax, 65 (2010), pp. 473-479
[19.]
C. LaForce, J. Aumann, P.L. De Teresa, A. Iqbal, D. Young, R. Owen, et al.
Sustained 24- hour efficacy of once daily indacaterol (300μg) in patients with chronic obstruc tive pulmonary disease: a randomized, crossover study.
Pulm Pharmacol Ther, 24 (2011), pp. 162-168
[20.]
H. Magnussen, C. Verkindre, D. Jack, D. Jadayel, M. Henley, R. Woessner, et al.
Indacaterol once-daily is equally effective dosed in the evening or morning in COPD.
Respir Med, 104 (2010), pp. 1869-1876
[21.]
C. Vogelmeier, D. Ramos-Barbon, D. Jack, S. Piggott, R. Owen, M. Higgins, et al.
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.
Respir Res, 11 (2010), pp. 135
[22.]
R. Buhl, L.J. Dunn, C. Disdier, C. Lassen, C. Amos, M. Henley, et al.
Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.
Eur Respir J, 38 (2011), pp. 797-803
[23.]
J.F. Donohue, C. Fogarty, J. Lotvall, D.A. Mahler, H. Worth, A. Yorgancioglu, et al.
Oncedaily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
Am J Respir Crit Care Med, 182 (2010), pp. 155-162
[24.]
M.P. Rutten-van Molken, J.B. Oostenbrink, M. Miravitlles, B.U. Monz.
Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.
Eur J Health Econ, 8 (2007), pp. 123-135
[25.]
R. Gani, J. Griffin, S. Kelly, M.M. Rutten-van.
Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD.
Prim Care Respir J, 19 (2010), pp. 68-74
[26.]
S. Naik, K.M. Kamal, P.A. Keys, T.J. Mattei.
Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease.
Clinic Outcomes Res, 2 (2010), pp. 25-36
[27.]
Y. Oba.
Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease.
Mayo Clin Proc, 82 (2007), pp. 575-582
[28.]
J.B. Oostenbrink, M.P. Rutten-van Molken, B.U. Monz, J.M. FitzGerald.
Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Value Health, 8 (2005), pp. 32-46
[29.]
D. Price, A. Gray, R. Gale, Y. Asukai, L. Mungapen, A. Lloyd, et al.
Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
Respir Med, 105 (2011), pp. 1635-1647
[30.]
N.S. Breekveldt-Postma, J. Koerselman, J.A. Erkens, J.W. Lammers, R.M. Herings.
Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.
Respir Med, 101 (2007), pp. 1398-1405
[31.]
J. Bourbeau, S.J. Bartlett.
Patient adherence in COPD.
Thorax, 63 (2008), pp. 831-838
[32.]
K.R. Chapman, C.M. Fogarty, C. Peckitt, C. Lassen, D. Jadayel, J. Dederichs, et al.
Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD.
Int J Chron Obstruct Pulmon Dis, 6 (2011), pp. 353-363
[33.]
K.F. Rabe, W. Timmer, A. Sagkriotis, K. Viel.
Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
Chest, 134 (2008), pp. 255-262
[34.]
R. Riemsma, S.K. Lhachimi, N. Armstrong, Van Asselt, A. Allen, N. Manning, et al.
Roflumilast for the management of severe chronic obstructive pulmonary disease: a Single Technology Appraisal.
Kleijnen Systematic Reviews Ltd, (2011),
[35.]
E.J. Mills, E. Druyts, I. Ghement, M.A. Puhan.
Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis.
Clin Epidemiol, 3 (2011), pp. 107-129
[36.]
G.A. Wells, S.A. Sultan, L. Chen, M. Khan, D. Coyle.
Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis.
Canadian Agency for Drugs and Technologies in Health, (2009),
[37.]
J.M. Singh, V.A. Palda, M.B. Stanbrook, K.R. Chapman.
Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review.
Arch Intern Med, 162 (2002), pp. 2527-2536
[38.]
M. Weatherall, J. Clay, K. James, K. Perrin, P. Shirtcliffe, R. Beasley.
Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis.
Respirology, 14 (2009), pp. 983-990
[39.]
National Institute for Health and Clinical Excellence (NICE). TA244 Chronic obstructive pulmonary disease-roflumilast: guidance. [sede Web] (acceso 19 Feb 2012). Disponible en: http://www.nice.org.uk/nicemedia/live/13649/57889/57889.pdf. 2012
[40.]
Merck Sharp & Dohme. Chronic obstructive pulmonary disease -roflumilast: Merck Sharp & Dohme. [Actualizado 7 Sept 2011; citado 18 Enero 2012]. Disponible en: http://guidance.nice.org.uk/TA/Wave24/13/Consultation/EvaluationReport/ManufacturerSubmissions/MSD/pdf/English.
[41.]
E.M. Grandjean, P.H. Berthet, R. Ruffmann, P. Leuenberger.
Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis.
Pharmacol Res, 42 (2000), pp. 39-50
[42.]
P. Poole, P.N. Black.
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2010), pp. CD001287
[43.]
C. Stey, J. Steurer, S. Bachmann, T.C. Medici, M.R. Tramer.
The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.
Eur Respir J, 16 (2000), pp. 253-262
[44.]
E.R. Sutherland, J.D. Crapo, R.P. Bowler.
N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease.
COPD, 3 (2006), pp. 195-202
[45.]
M.A. Tan-Reyes.
The role of N-acetylcysteine in reducing number of exacerbations in patients with moderate to severe chronic obstructive pulmonary disease; a meta-analysis.
Respirology, 14 (2009), pp. A268
[46.]
A. Sayiner, Z.A. Aytemur.
N-acetylcysteine in exacerbations of chronic obstrutive pulmonary disease associated with increased sputum [abstract].
Am J Respir Crit Care Med, 183 (2011), pp. A3123
[47.]
T. Schermer, N. Chavannes, R. Dekhuijzen, E. Wouters, J. Muris, R. Akkermans, et al.
Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.
Respir Med, 103 (2009), pp. 542-551
[48.]
D. Stav, M. Raz.
Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study.
Chest, 136 (2009), pp. 381-386
[49.]
Long-term oral acetylcysteine in chronic bronchitis. a double-blind controlled study.
Eur J Respir Dis Suppl, 111 (1980), pp. 93-108
[50.]
A.A. Bachh, N.N. Shah, R. Bhargava, et al.
Effect of oral N-Acetylcysteine in COPD-a randomised controlled trial.
JK-Practitioner, 14 (2007), pp. 12-16
[51.]
G. Boman, U. Backer, S. Larsson, B. Melander, L. Wahlander.
Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases.
Eur J Respir Dis, 64 (1983), pp. 405-415
[54.]
M. Borgia, N. Sepe, M. Ori-Belometti, R. Borgia.
Comparison between acetylcysteine and placebo in the long term treatment of chronic bronchitis [Confronto tra acetilcisteina e placebo nel trattamento a lungo termine della bronchite cronica].
Gazzetta Medica Italiana, 140 (1981), pp. 467-472
[53.]
British Thoracic Society Research Committee.
Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction.
Thorax, 40 (1985), pp. 832-835
[54.]
M. Decramer, M.M. Rutten-van, P.N. Dekhuijzen, T. Troosters, H.C. Van, R. Pellegrino, et al.
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
Lancet, 365 (2005), pp. 1552-1560
[55.]
C. Grassi, G.C. Morandini.
A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis.
Eur J Clin Pharmacol, 09 (1976), pp. 393-396
[56.]
N.C. Hansen, A. Skriver, L. Brorsen-Riis, S. Balslov, T. Evald, N. Maltbaek, et al.
Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis.
Respir Med, 88 (1994), pp. 531-535
[57.]
I.M. Jackson, J. Barnes, P. Cooksey.
Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: a double-blind placebo controlled study.
J Int Med Res, 12 (1984), pp. 198-206
[58.]
R. Meister.
Long-term therapy with acetylcysteine retard tablets in patients with chronic bronchitis:a double-blind, (1986),
[59.]
D. Nowak, L. Carati, M. Pirozynski.
Long-term administration of N-acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease:report of the BREATHE study.
Eur Resp J, 14 (1999), pp. 381S-382S
[60.]
G.D. Parr, A. Huitson.
Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis.
Br J Dis Chest, 81 (1987), pp. 341-348
[61.]
R. Pela, A.M. Calcagni, S. Subiaco, P. Isidori, A. Tubaldi, C.M. Sanguinetti.
N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.
Respiration, 66 (1999), pp. 495-500
[62.]
J.B. Rasmussen, C. Glennow.
Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis.
Eur Respir J, 1 (1988), pp. 351-355
[63.]
C. Grassi, L. Casali, A. Ciaccia, et al.
Terapia intervallare con l’associazione carbocisteina- sobrerolo nella profilassi delle riacutizzazioni della bronchite cronica.
Italian J Chest Dis, 48 (1994), pp. 17-26
[64.]
L. Allegra, C.I. Cordaro, C. Grassi.
Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial.
Respiration, 63 (1996), pp. 174-180
[65.]
J.P. Zheng, J. Kang, S.G. Huang, P. Chen, W.Z. Yao, L. Yang, et al.
Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study.
Lancet, 371 (2008), pp. 2013-2018
[66.]
M. Grillage, K. Barnard-Jones.
Long-term oral carbocisteine therapy in patients with chronic bronchitis. A double blind trial with placebo control.
Br J Clin Pract, 39 (1985), pp. 395-398
[67.]
J.A. Walters, P.G. Gibson, R. Wood-Baker, M. Hannay, E.H. Walters.
Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2009), pp. CD001288
[69.]
B.S. Quon, W.Q. Gan, D.D. Sin.
Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis.
Chest, 133 (2008), pp. 756-766
[70.]
J.A. Riancho, I. Portero, I. Cubian.
Eficacia de los glucocorticoides en las reagudizaciones de la enfermedad pulmonar obstructiva cronica: metaanalisis de los estudios publicados.
Med Clin (Barc), 114 (2000), pp. 681-684
[71.]
T.A. Schweiger, M. Zdanowicz.
Systemic corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease.
Am J Health Syst Pharm, 67 (2010), pp. 1061-1069
[72.]
S.D. Aaron, K.L. Vandemheen, P. Hebert, R. Dales, I.G. Stiell, J. Ahuja, et al.
Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease.
N Engl J Med, 348 (2003), pp. 2618-2625
[73.]
W.H. Thompson, C.P. Nielson, P. Carvalho, N.B. Charan, J.J. Crowley.
Controlled trial of oral prednisone in outpatients with acute COPD exacerbation.
Am J Respir Crit Care Med, 154 (1996), pp. 407-412
[74.]
D.U. Jette, M.C. Bourgeois, R. Buchbinder.
Pulmonary rehabilitation following acute exacerbation of chronic obstructive pulmonary disease.
Phys Ther, 9 (2010), pp. 9-12
[75.]
D.D. Marciniuk, D. Brooks, S. Butcher, R. Debigare, G. Dechman, G. Ford, et al.
Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease: practical issues: a Canadian Thoracic Society Clinical Practice Guideline.
Can Respir J, 17 (2010), pp. 159-168
[76.]
A.L. Ries, G.S. Bauldoff, B.W. Carlin, R. Casaburi, C.F. Emery, D.A. Mahler, et al.
Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines.
Chest, 131 (2007), pp. 4S-42S
[77.]
M.A. Puhan, E. Gimeno-Santos, M. Scharplatz, T. Troosters, E.H. Walters, J. Steurer.
Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, (2011), pp. CD005305
[78.]
J.M. Seymour, L. Moore, C.J. Jolley, K. Ward, J. Creasey, J.S. Steier, et al.
Outpatient pulmonary rehabilitation following acute exacerbations of COPD.
Thorax, 65 (2010), pp. 423-428
[79.]
N. Murphy, C. Bell, R.W. Costello.
Extending a home from hospital care programme for COPD exacerbations to include pulmonary rehabilitation.
Respir Med, 99 (2005), pp. 1297-1302
[80.]
W.D. Man, M.I. Polkey, N. Donaldson, B.J. Gray, J. Moxham.
Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study.
Br Med J, 329 (2004), pp. 1209
[81.]
M. Ghanem, E.A. Elaal, M. Mehany, K. Tolba.
Home-based pulmonary rehabilitation program: effect on exercise tolerance and quality of life in chronic obstructive pulmonary disease patients.
Ann Thorac Med, 5 (2010), pp. 18-25
[82.]
E.M. Clini, E. Crisafulli, S. Costi, G. Rossi, C. Lorenzi, L.M. Fabbri, et al.
Effects of early inpatient rehabilitation after acute exacerbation of COPD.
Respir Med, 103 (2009), pp. 1526-1531
[83.]
M.C. Fiore, C.R. Jaén, T.G. Baker, W.C. Bailey, N.L. Benowitz, S.J. Curry, et al.
Treating tobacco use and dependence: 2008 Update. Clinical Practice Guideline.
US Department of Health and Human Services, Public Health Service, (2008),
[84.]
N.R. Anthonisen, M.A. Skeans, R.A. Wise, J. Manfreda, R.E. Kanner, J.E. Connett.
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.
Ann Intern Med, 142 (2005), pp. 233-239
[85.]
V.S. Peña, M. Miravitlles, R. Gabriel, C.A. Jimenez-Ruiz, C. Villasante, J.F. Masa, et al.
Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study.
Chest, 118 (2000), pp. 981-989
[86.]
N.S. Godtfredsen, T.H. Lam, T.T. Hansel, M.E. Leon, N. Gray, C. Dresler, et al.
COPD-related morbidity and mortality after smoking cessation: status of the evidence.
Eur Respir J, 32 (2008), pp. 844-853
[87.]
M.N. Hylkema, P.J. Sterk, W.I. De Boer, D.S. Postma.
Tobacco use in relation to COPD and asthma.
Eur Respir J, 29 (2007), pp. 438-445
[88.]
Wagy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review.
Respir Med, 98 (2004), pp. 805-815
[89.]
C.A. Jiménez Ruiz, J.I. De Granda Orive, J.A. Riesco Miranda.
Abordaje diagnóstico y terapéutico del tabaquismo en EPOC.
Tratado de rehabilitación respiratoria,
[90.]
C. Cabezas, T. Robledo de Dios, F. Marqués, R. Ortega, M.J. Megido.
Recomendaciones sobre el estilo de vida.
Aten Primaria, 39 (2007), pp. 27-46
[91.]
B.M. Sundblad, K. Larsson, L. Nathell.
High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization.
Nicotine Tob Res, 10 (2008), pp. 883-890
[92.]
D. Wang, M. Connock, P. Barton, A. Fry-Smith, P. Aveyard, D. Moore.
‘Cut down to quit’ with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.
Health Technol Assess, 12 (2008), pp. iii-xi
[93.]
L. Christenhusz, M. Pieterse, E. Seydel, P.J. Van der.
Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention.
Patient Educ Couns, 66 (2007), pp. 162-166
[94.]
T.J. Crowley, A.E. Andrews, J. Cheney, G. Zerbe.
Carbon monoxide assessment of smoking in Chronic Obstructive Pulmonary Disease.
Addictive Behaviors, 14 (1989), pp. 493-502
[95.]
T.J. Crowley, M.J. Macdonald, M.I. Walter.
Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients.
Psychopharmacology (Berl), 119 (1995), pp. 193-204
[96.]
S.R. Hilberink, J.E. Jacobs, M.H. Breteler, V.H. De, R.P. Grol.
General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions.
Patient Educ Couns, 83 (2011), pp. 120-124
[97.]
E. Monninkhof, P.J. Van der, H. Mulder, et al.
The effect of a minimal contact smoking cessation programme in out-patients with chronic obstructive pulmonary disease: a pre-post-test study.
Patient Educ Couns, 52 (2004), pp. 231-236
[98.]
L.L. Pederson, J.M. Wanklin, N.M. Lefcoe.
The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial.
Int J Addict, 26 (1991), pp. 107-119
[99.]
S.A. Turner, J.L. Daniels, J.G. Hollandsworth.
The effects of a multicomponent smoking cessation program with chronic obstructive pulmonary disease outpatients.
Addict Behav, 10 (1985), pp. 87-90
[100.]
J.S. Wilson, D. Fitzsimons, I. Bradbury, E.J. Stuart.
Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial.
Int J Nurs Stud, 45 (2008), pp. 508-517
[101.]
P. Tonnesen, K. Mikkelsen, L. Bremann.
Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support.
Chest, 130 (2006), pp. 334-342
[102.]
C.P. Van Schayck, J. Kaper, E.J. Wagena, E.F. Wouters, J.L. Severens.
The cost-effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients.
Addiction, 104 (2009), pp. 2110-2117
[103.]
M. Hoogendoorn, T.L. Feenstra, R.T. Hoogenveen, M.P. Rutten-van Mölken.
Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD.
Thorax, 65 (2010), pp. 711-718
[104.]
I. Berlin, N. Jacob, M. Coudert, J. Perriot, L. Schultz, N. Rodon.
Adjustment of nicotine replacement therapies according to saliva cotinine concentration: the ADONIS* trial-a randomized study in smokers with medical comorbidities.
Addiction, 106 (2011), pp. 833-843
[105.]
R. Strassmann, B. Bausch, A. Spaar, J. Kleijnen, O. Braendli, M.A. Puhan.
Smoking cessation interventions in COPD: a network meta-analysis of randomised trials.
Eur Respir J, 34 (2009), pp. 634-640
[106.]
I. Berlin.
Therapeutic strategies to optimize the efficacy of nicotine replacement therapies.
COPD, 6 (2009), pp. 272-276
[107.]
D. Moore, P. Aveyard, M. Connock, D. Wang, A. Fry-Smith, P. Barton.
Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis.
Br Med J, 338 (2009), pp. b1024
[108.]
R. Richmond, N. Zwar.
Review of bupropion for smoking cessation.
Drug Alcohol Rev, 22 (2003), pp. 203-220
[109.]
D. Tashkin, R. Kanner, W. Bailey, S. Buist, P. Anderson, M. Nides, et al.
Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial.
Lancet, 357 (2001), pp. 1571-1575
[110.]
E.J. Wagena, P.G. Knipschild, M.J. Huibers, E.F. Wouters, C.P. Van Schayck.
Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease.
Arch Intern Med, 165 (2005), pp. 2286-2292
[111.]
K. Bolin, K. Wilson, H. Benhaddi, et al.
Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation: results from four European countries.
Eur J Public Health, 19 (2009), pp. 650-654
[112.]
J.O. Ebbert, K.D. Wyatt, A. Zirakzadeh, M.V. Burke, J. Hays.
Clinical utility of varenicline for smokers with medical and psychiatric comorbidity.
Int J Chron Obstruct Pulmon Dis, 4 (2009), pp. 421-430
[113.]
U.M. Mohanasundaram, R. Chitkara, G. Krishna.
Smoking cessation therapy with varenicline.
Int J Chron Obstruct Pulmon Dis, 3 (2008), pp. 239-251
[114.]
D.P. Tashkin, S. Rennard, J.T. Hays, W. Ma, D. Lawrence, T.C. Lee.
Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial.
Chest, 139 (2011), pp. 591-599
[115.]
Nota informativa del 9 de enero de 2008 de la Agencia Española de Medicamentos y Productos Sanitarios sobre la revisión de la información de seguridad de la vareniclina en Europa. [sede Web] (acceso 5 Ene 2012), Disponible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2008/NI_2008-01_vareniclina.htm.
[116.]
E.C. Hansen, J. Walters, R.W. Baker.
Explaining chronic obstructive pulmonary disease (COPD): perceptions of the role played by smoking.
Sociol Health Illn, 29 (2007), pp. 730-749
[117.]
I. Schofield, S. Kerr, D. Tolson.
An exploration of the smoking-related health beliefs of older people with chronic obstructive pulmonary disease.
J Clin Nurs, 16 (2007), pp. 1726-1735
[118.]
J.S. Wilson, J.S. Elborn, D. Fitzsimons.
‘It's not worth stopping now’: why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study.
J Clin Nurs, 20 (2011), pp. 819-827
[119.]
L. Winstanley, M. Daunt, J. Macfarlane.
Doctors’ attitude towards current smokers with chronic obstructive pulmonary disease and its impact on delivering smoking cessation advice.
J Smoking Cessation, 3 (2008), pp. 133-135
[120.]
M.W. Zhang, R.C. Ho, M.W. Cheung, E. Fu, A. Mak.
Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression.
Gen Hosp Psychiatry, 33 (2011), pp. 217-223
[121.]
K. Hill, R. Geist, R.S. Goldstein, Y. Lacasse.
Anxiety and depression in end-stage COPD.
Eur Respir J, 31 (2008), pp. 667-677
[122.]
C.M. Bosley, Z.M. Corden, P.J. Rees, G.M. Cochrane.
Psychological factors associated with use of home nebulized therapy for COPD.
Eur Respir J, 9 (1996), pp. 2346-2350
[123.]
R. Garrod, J. Marshall, E. Barley, P.W. Jones.
Predictors of success and failure in pulmonary rehabilitation.
Eur Respir J, 27 (2006), pp. 788-794
[124.]
D.B. Coultas, D.W. Edwards, B. Barnett, P. Wludyka.
Predictors of depressive symptoms in patients with COPD and health impact.
COPD, 4 (2007), pp. 23-28
[125.]
A.M. Yohannes, R.C. Baldwin, M.J. Connolly.
Depression and anxiety in elderly outpatients with chronic obstructive pulmonary disease: prevalence, and validation of the BASDEC screening questionnaire.
Int J Geriatr Psychiatry, 15 (2000), pp. 1090-1096
[126.]
H.C. McCathie, S.H. Spence, R.L. Tate.
Adjustment to chronic obstructive pulmonary disease: the importance of psychological factors.
Eur Respir J, 19 (2002), pp. 47-53
[127.]
Management of COPD Working Group.
VA/DoD clinical practice guideline for the management of outpatient chronic obstructive pulmonary disease.
Department of Veterans Affairs, Department of Defense, (2007),
[128.]
National Collaborating Centre for Mental Health.
Depression in adults with a chronic physical health problem: treatment and management.
National Institute for Health and Clinical Excellence(NICE), (2009),
[129.]
A.G. Gift, S.H. McCrone.
Depression in patients with COPD.
Heart Lung, 22 (1993), pp. 289-297
[131.]
N. Eiser, R. Harte, K. Spiros, C. Phillips, M.T. Isaac.
Effect of treating depression on quality-of-life and exercise tolerance in severe COPD.
COPD, 2 (2005), pp. 233-241
[132.]
Y. Lacasse, L. Beaudoin, L. Rousseau, F. Maltais.
Randomized trial of paroxetine in end-stage COPD.
Monaldi Arch Chest Dis, 61 (2004), pp. 140-147
[133.]
E.J. Silvertooth, P.M. Doraiswamy, G.L. Clary, M.A. Babyak, N. Wilkerson, C. Hellegars, et al.
Citalopram and quality of life in lung transplant recipients.
Psychosomatics, 45 (2004), pp. 271-272
[134.]
R.W. Light, E.J. Merrill, J. Despars, G.H. Gordon, L.R. Mutalipassi.
Doxepin treatment of depressed patients with chronic obstructive pulmonary disease.
Arch Intern Med, 146 (1986), pp. 1377-1380
[135.]
S. Borson, G.J. McDonald, T. Gayle, M. Deffebach, S. Lakshminarayan, C. VanTuinen.
Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease.
Psychosomatics, 33 (1992), pp. 190-201
[136.]
Z.A. Usmani, K.V. Carson, J.N. Cheng, A.J. Esterman, B.J. Smith.
Pharmacological interventions for the treatment of anxiety disorders in chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, 11 (2011), pp. CD008483
[137.]
A. Baraniak, D. Sheffield.
The efficacy of psychologically based interventions to improve anxiety, depression and quality of life in COPD: a systematic review and meta-analysis.
Patient Educ Couns, 83 (2011), pp. 29-36
[138.]
M.J. Hynninen, N. Bjerke, S. Pallesen, P.S. Bakke, I.H. Nordhus.
A randomized controlled trial of cognitive behavioral therapy for anxiety and depression in COPD.
Respir Med, 104 (2010), pp. 986-994
[139.]
F. Lamers, C.C. Jonkers, H. Bosma, N.H. Chavannes, J.A. Knottnerus, J.T. Van Eijk.
Improving quality of life in depressed COPD patients: effectiveness of a minimal psychological intervention.
COPD, 7 (2010), pp. 315-322
[140.]
P.A. Coventry, D. Hind.
Comprehensive pulmonary rehabilitation for anxiety and depression in adults with chronic obstructive pulmonary disease: Systematic review and meta-analysis.
J Psychosom Res, 63 (2007), pp. 551-565
[141.]
H. Paz-Diaz, O.M. Montes de, J.M. Lopez, B.R. Celli.
Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD.
Am J Phys Med Rehabil, 86 (2007), pp. 30-36
Copyright © 2012. Sociedad Española de Neumología y Cirugía Torácica
